Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.

Mitra Rashidi, Sorosh Esmaily, Arnt E Fiane, Einar Gude, Kim A Tønseth, Thor Ueland, Finn Gustafsson, Hans Eiskjær, Göran Rådegran, Göran Dellgren

Research output: Contribution to journalArticlepeer-review

Abstract

The use of mammalian target of rapamycin (mTOR) inhibitors have been limited by adverse events (AE), including delayed wound healing. We retrospectively reviewed all AE and serious AE (SAE) in The Scandinavian heart transplant (HTx) everolimus (EVE) de novo trial with early calcineurin (CNI) avoidance (SCHEDULE). The aim of the study was to compare wound complications between EVE and CNI based regimen.
Original languageEnglish
Pages (from-to)80-84
JournalInternational Journal of Cardiology
Volume210
DOIs
Publication statusPublished - 2016

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Fingerprint

Dive into the research topics of 'Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.'. Together they form a unique fingerprint.

Cite this